BridgeBio Pharma (BBIO) Non-Current Assets (2018 - 2026)

BridgeBio Pharma has disclosed Non-Current Assets across 9 years of filings, most recently posting $129.7 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $129.7 million, down 30.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $594.7 million (down 24.11% YoY), and the FY2025 annual result was $138.3 million, down 30.39% from the prior year.
• Non-Current Assets came in at $129.7 million for Q1 2026 at BridgeBio Pharma, down from $138.3 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $220.4 million in Q3 2024 to a low of $65.9 million in Q1 2024.
• The 5-year median for Non-Current Assets is $96.9 million (2022), against an average of $121.9 million.
• Across the five-year window, Non-Current Assets sank 47.0% in 2022 and soared 227.3% in 2024, its largest moves.
• BridgeBio Pharma's Non-Current Assets stood at $74.2 million in 2022, then retreated by 7.27% to $68.8 million in 2023, then jumped by 188.78% to $198.6 million in 2024, then slumped by 30.39% to $138.3 million in 2025, then decreased by 6.22% to $129.7 million in 2026.
• The last three Non-Current Assets figures came in at $129.7 million (Q1 2026), $138.3 million (Q4 2025), and $158.9 million (Q3 2025), per Business Quant data.